XML 26 R15.htm IDEA: XBRL DOCUMENT

Grant Income	6 Months Ended
Jun. 30, 2025
Grant Income
Grant Income	(7)Grant Income In September 2024, the Company received its second Award (the “2024 Award”) from the National Cancer Institute of the National Institutes of Health (the “NIH”). The 2024 Award is a Direct to Phase II SBIR Award to support IND-enabling and clinical trial activities in the Company’s clinical trial with its lead candidate, TTX-MC138, over two years. The total 2024 Award is for $1,999,972 of which $1,011,207 applies to the first year and $988,765 applies to the second year. The Company recognized grant income of $153,685 and $0 for the three months ended June 30, 2025 and 2024, respectively, and $501,529 and $27,057, respectively, for the six months ended June 30, 2025, and 2024. The Company had deferred grant income of $0 at June 30, 2025, and $25,408 at December 31, 2024, respectively.

Grant Income

6 Months Ended

Jun. 30, 2025

(7)Grant Income

In September 2024, the Company received its second Award (the “2024 Award”) from the National Cancer Institute of the National Institutes of Health (the “NIH”). The 2024 Award is a Direct to Phase II SBIR Award to support IND-enabling and clinical trial activities in the Company’s clinical trial with its lead candidate, TTX-MC138, over two years. The total 2024 Award is for $1,999,972 of which $1,011,207 applies to the first year and $988,765 applies to the second year.

The Company recognized grant income of $153,685 and $0 for the three months ended June 30, 2025 and 2024, respectively, and $501,529 and $27,057, respectively, for the six months ended June 30, 2025, and 2024. The Company had deferred grant income of $0 at June 30, 2025, and $25,408 at December 31, 2024, respectively.